Products > Antibodies > Polyclonal Antibodies

Categories

Rabbit Anti-Human Lyve-1

DatasheetFiguresProtocolReference

Order Form

Slide this table

Cat-Nr.102-PA50
Size200 µg
Price305 €
CategoryPolyclonal Antibody
Clone Nr.Rabbit IgG
Species ReactivityHuman
Formulationlyophilized
BufferPBS
ReconstitutionCentrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
Stability and StorageThe lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.
PreparationProduced from sera of rabbits immunized with highly pure recombinant human soluble LYVE-1 produced in insect cells. The recombinant soluble LYVE-1consists of amino acid 24 (Ser) to 232 (Gly) and is fused to a C-terminal His-tag (6xHis). LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule co-localizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
AntigenRecombinant human LYVE-1 (RT #S01-028)
ApplicationWB, IHC (P, F), IF
SynonymsLYVE1; HAR; XLKD1; LYVE-1; CRSBP-1
DescriptionLYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
Uniprot IDQ9Y5Y7
Protein RefSeqNP_006682
mRNA RefSeqNM_006691

Figures

Figure 1.
Cryo sections of human colon carcinoma labeled with rabbit polyclonal antibody against human LYVE-1 (red) [Cat# 102-PA50] and human CD31 (green). A: CD31; B: LYVE-1; C: CD31/LYVE-1
Figure 2.
Immunohistochemistry with paraffin-embedded sections of human intestine (border area of a colon carcinoma) using a polyclonal rabbit anti-human [Cat# 102-PA50] LYVE-1 antibody. You see the staining (red) of lymphatic endothelial cells of the intestine.
The experiments has been performed by Dr. Karsten Debel, DCS, Hamburg, Germany.
Figure 3.
Western analysis of recombinant human sLYVE - 1[Cat# S01-028] and mouse sLYVE -1[Cat# S01-026] using an anti-human LYVE-1 polyclonal antibody [Cat# 102-PA 50] directed against the extracellular domain of human LYVE-1. There is more or less no cross reactivity with mouse LYVE-1.
Figure 4.
FACS analysis with primary human dermal microvascular endothelial cells (HDMVEC).

Protocol

a) For IF with LECPDF download
b) For FACSPDF download

 

Reference

  1. Upregulation of VCAM-1 in lymphatic collectors supports dendritic cell entry and rapid migration to lymph nodes in inflammation. J. Arasa et al., J Exp Med. 2021 Jul 5; 218(7): e20201413.
  2. A Single-Cell Transcriptional Roadmap of the Mouse and Human Lymph Node Lymphatic Vasculature. M. Xiang et al., Front Cardiovasc Med. 2020; 7: 52.
  3. TGFβ counteracts LYVE-1-mediated induction of lymphangiogenesis by small hyaluronan oligosaccharides. Bauer J. et al., J Mol Med (Berl). 2018 Feb;96(2):199-209.
  4. Engineering Blood and Lymphatic Microvascular Networks in Fibrin Matrices. L. Knezevic et al., Front Bioeng Biotechnol. 2017; 5: 25.  
  5. ELM: A New, Simple, and Economic Assay to Measure Motility of Lymphatic Endothelial Cells. F. Torri et al., Lymphat Res Biol. 2017 Mar 1; 15(1): 39–44.
  6. Tissue-engineered 3D human lymphatic microvascular network for in vitro studies of lymphangiogenesis. Gibot L et al. Nat Protoc. 2017 May;12(5):1077-1088.
  7. Inflammation and Lymphedema Are Exacerbated and Prolonged by Neuropilin 2 Deficiency. P. Mucka et al., Am J Pathol. 2016 Nov; 186(11): 2803–2812.
  8. Orbital angiogenesis and lymphangiogenesis in thyroid eye disease: an analysis of vascular growth factors with clinical correlation. L. L. Wong et al., Ophthalmology. 2 16 Sep; 123(9): 2028–2036.
  9. Morphological and Molecular Characterization of Human Dermal Lymphatic Collectors. V. Hasselhof et al., PLoS One. 2016; 11(10): e0164964.  
  10. Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer. M. Kleppe et al., Int J Gynecol Cancer. 2015 Oct; 25(8): 1405–1414.  
  11. Development of full-thickness human skin equivalents with blood and lymph-like capillary networks by cell coating technology. Matsusaki M. et al., J Biomed Mater Res A. 2015 Oct;103(10):3386-96.
  12. TGF-β1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis. M-F Pang et al., Oncogene. 2016 Feb 11; 35(6): 748–760.
  13. Generation of pure lymphatic endothelial cells from human pluripotent stem cells and their therapeutic effects on wound repair. Shin-Jeong Lee et al., Sci Rep. 2015; 5: 11019.  
  14. Adhesion of Pancreatic Cancer Cells in a Liver-Microvasculature Mimicking Coculture Correlates with Their Propensity to Form Liver-Specific Metastasis In Vivo. M. M. Chowdhury et al., Biomed Res Int. 2014; 2014: 241571.  
  15. Arterial wall lymphangiogenesis is increased in the human iliac atherosclerotic arteries: involvement of CCR7 receptor. Grzegorek I et al. Lymphat Res Biol. 2014 Dec;12(4):222-31.
  16. Pivotal roles of lymphatic endothelial cell layers in the permeability to hydrophilic substances through collecting lymph vessel walls: effects of inflammatory cytokines. Kawai Y et al., Lymphat Res Biol. 2014 Sep;12(3):124-35.
  17. Molecular and Cellular Effects of In Vitro Shockwave Treatment on Lymphatic Endothelial Cells. S. Rohringer et al. PLoS One. 2014; 9(12): e114806.  
  18. Plasticity of Blood- and Lymphatic Endothelial Cells and Marker Identification. J. Keuschnigg et al., PLoS One. 2013; 8(9): e74293.  
  19. High density of peritumoral lymphatic vessels measured by D2-40/podoplanin and LYVE-1 expression in gastric cancer patients: an excellent prognostic indicator or a false friend?    J. Rudno-Rudzinska et al., Gastric Cancer. 2013; 16(4): 513–520.  
  20. Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. Rahier JF et al., Aliment Pharmacol Ther. 2011 Sep;34(5):533-43.
  21. Lack of Evidence for the Direct Activation of Endothelial Cells by Adult Female and Microfilarial Excretory-Secretory Products. T. Weinkopff and Patrick Lammie, PLoS One. 2011; 6(8): e22282.  
  22. An exquisite cross-control mechanism among endothelial cell fate regulators directs the plasticity and heterogeneity of lymphatic endothelial cells. J. Kang et al. Blood. 2010 Jul 8; 116(1): 140–150.
Order Form
Back to overview

All prices plus VAT + possible delivery charges

© 2024 ReliaTech. All Rights Reserved – Lyve-1 (102-PA50)